文献速递头颈部肿瘤放疗

单纯同步放化疗治疗局部区域晚期鼻咽癌的疗效:长期随访分析

Efficacy of concurrent chemoradiotherapy alone for loco-regionally advanced nasopharyngeal carcinoma: long-term follow-up analysis.
PubMed 文献 · Radiat Oncol · 2023-04-05

本研究基于10年随访结果分析单纯同步放化疗治疗局部区域晚期鼻咽癌的临床结局。共纳入456例III-IVa期患者,接受根治性调强放疗和同步顺铂化疗。按死亡风险相对HR分为低危(HR<2,244例)、中危(HR 2-5,140例)和高危(HR>5,72例)三组,10年总生存率分别为86%、71%和52%,组间差异均有统计学意义。作者认为单纯调强放疗加顺铂可能适合低危患者,而不适合中危和高危患者。

要点

  • 10年总生存率为76%,10年局部区域无失败生存率、远处无失败生存率和无失败生存率分别为72%、73%和70%。
  • 按相对死亡风险HR分为低危(T1-2N2和T3N0-1,HR<2,244例)、中危(T3N2和T4N0-1,HR 2-5,140例)和高危(T4N2和T1-4N3,HR>5,72例)。
  • 低、中、高危组10年总生存率分别为86%、71%和52%,两两比较差异均有统计学意义。

核心结论

  • 本分类标准表明局部区域晚期鼻咽癌患者不同TNM亚分期之间死亡风险存在显著异质性。
  • 作者认为单纯调强放疗加顺铂可能适合低危局部区域晚期鼻咽癌(T1-2N2或T3N0-1),但不适合中危和高危患者。
  • 这些预后分组为未来临床试验中指导个体化治疗和选择最佳靶向提供了解剖学基础。

研究设计与样本

  • 连续纳入III-IVa期(AJCC/UICC第8版)局部区域晚期鼻咽癌患者456例。
  • 所有患者接受根治性调强放疗和同步顺铂化疗。
  • 以T3N0患者的死亡风险HR为基线,通过Cox比例风险模型计算相对HR以划分不同死亡风险患者。
  • 采用Kaplan-Meier法分析时间-事件终点生存曲线,并用log-rank检验比较。
  • 所有统计检验采用双侧显著性水平0.05。

主要发现

  • 中位随访12年,10年总生存率为76%。
  • 10年局部区域无失败生存率、远处无失败生存率和无失败生存率分别为72%、73%和70%。
  • 低危组(T1-2N2和T3N0-1,HR<2)244例,中危组(T3N2和T4N0-1,HR 2-5)140例,高危组(T4N2和T1-4N3,HR>5)72例。
  • 低、中、高危组10年总生存率分别为86%、71%和52%。
  • 总生存率两两比较:低危组 vs 中危组 P<0.001;低危组 vs 高危组 P<0.001;中危组 vs 高危组 P=0.002。

关键数值与推荐

  • 3-4级晚期毒性包括耳聋/中耳炎9%、口干4%、颞叶损伤5%、颅神经病变4%、周围神经病变2%、软组织损伤2%和牙关紧闭1%。

临床怎么用

  • 作者认为单纯调强放疗加顺铂可能适合低危局部区域晚期鼻咽癌(T1-2N2或T3N0-1),但不适合中危和高危患者。
  • 这些预后分组为未来临床试验中指导个体化治疗和选择最佳靶向提供了解剖学基础。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To analysis the clinical outcomes of concurrent chemoradiotherapy (CCRT) alone based on 10-year results for loco-regionally advanced nasopharyngeal carcinoma (LANPC), so as to provide evidence for individualized treatment strategy and designing appropriate clinical trial for different risk LANPC patients. METHODS: Consecutive patients with stage III-IVa (AJCC/UICC 8th) were enrolled in this study. All patients received radical intensity-modulated radiotherapy (IMRT) and concurrent cisplatin chemotherapy (CDDP). The hazard ratios (HRs) of death risk in patients with T3N0 was used as baseline, relative HRs were calculated by a Cox proportional hazard model to classify different death risk patients. Survival curves for the time-to-event endpoints were analyzed by the Kaplan-Meier method and compared using the log-rank test. All statistical tests were conducted at a two-sided level of significance of 0.05. RESULTS: A total of 456 eligible patients were included. With 12-year median follow-up, 10-year overall survival (OS) was 76%. 10-year loco-regionally failure-free survival (LR-FFS), distant failure-free survival (D-FFS) and failure-free survival (FFS) were 72%, 73% and 70%, respectively. Based on the relative hazard ratios (HRs) of death risk, LANPC patients were classified into 3 subgroups, low-risk group (T1-2N2 and T3N0-1) contained 244 patients with HR < 2; medium-risk group (T3N2 and T4N0-1) contained 140 patients with HR of 2 - 5; high-risk group (T4N2 and T1-4N3) contained 72 patients with HR > 5. The 10-year OS for patients in low-, medium-, and high-risk group were 86%, 71% and 52%, respectively. Significantly differences of OS rates were found between each of the two groups (low-risk group vs. medium-risk group, P < 0.001; low-risk group vs. high-risk group, P < 0.001; and medium-risk group vs. high-risk group, P = 0.002, respectively). Grade 3-4 late toxicities included deafness/otitis (9%), xerostomia (4%), temporal lobe injury (5%), cranial neuropathy (4%), peripheral neuropathy (2%), soft tissue damage (2%) and trismus (1%). CONCLUSIONS: Our classification criteria demonstrated that significant heterogeneity in death risk among TN substages for LANPC patients. IMRT plus CDDP alone maybe suitable for low-risk LANPC (T1-2N2 or T3N0-1), but not for medium- and high-risk patients. These prognostic groupings provide a practicable anatomic foundation to guide individualized treatment and select optimal targeting in the future clinical trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Xu AA, Miao JJ, Wang L, et al. Efficacy of concurrent chemoradiotherapy alone for loco-regionally advanced nasopharyngeal carcinoma: long-term follow-up analysis. Radiat Oncol. 2023. PMID: 37020312. doi:10.1186/s13014-023-02247-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。